Interstitial pneumonitis after treatment with pemetrexed for non-small cell lung cancer

Cancer Research and Treatment

Volumn 45, Issue 1, 2013, Pages 74-77

  Kim, Kyeong Hyun ^a   Song, Seo Young ^a   Lim, Kyu Hyoung ^a   Han, Seon Sook ^a   Kim, Se Hyun ^a   Cho, Jun Hwi ^a   Park, Chan Woo ^a   Lee, Seoungkoo ^a   Lee, Hui Young ^a  

^a Kangwon National University   (South Korea)

Author keywords

Adenocarcinoma; Drug therapy; Interstitial lung diseases; Non small cell lung carcinoma; Pemetrexed

Indexed keywords

C REACTIVE PROTEIN; CARBOPLATIN; COTRIMOXAZOLE; ERLOTINIB; GEMCITABINE; LACTATE DEHYDROGENASE; LEVOFLOXACIN; PEMETREXED; PREDNISOLONE; STEROID;

AGED; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BLOOD GAS ANALYSIS; BONE METASTASIS; BRONCHOSCOPY; CANCER GROWTH; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPNEA; FEVER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERSTITIAL PNEUMONIA; LABORATORY TEST; LUNG ADENOCARCINOMA; LUNG AUSCULTATION; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; SMOKING; THORAX RADIOGRAPHY; TREATMENT OUTCOME; VIDEO ASSISTED THORACOSCOPIC SURGERY; VITAL SIGN; VITAMIN SUPPLEMENTATION;

EID: 84879070670     PISSN: 15982998     EISSN: 20059256     Source Type: Journal    
DOI: 10.4143/crt.2013.45.1.74     Document Type: Article

References (7)

1. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543-51.
2. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589-97.
3. Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009;374:1432-40.
4. Sun JM, Lee KW, Kim JH, Kim YJ, Yoon HI, Lee JH, et al. Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer. Jpn J Clin Oncol. 2009;39:27-32.
5. Ohe Y, Ichinose Y, Nakagawa K, Tamura T, Kubota K, Yamamoto N, et al. Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer. Clin Cancer Res. 2008;14:4206-12.
6. Kim HO, Lee SY, Shim JJ, Kang KH, Shin BK. A case of pemetrexedinduced acute lung injury in non-small cell lung cancer. J Thorac Oncol. 2010;5:401-2.
7. Muller NL, White DA, Jiang H, Gemma A. Diagnosis and management of drug-associated interstitial lung disease. Br J Cancer. 2004;91 Suppl 2:S24-30.